Related Experiment Video
Updated: May 30, 2026

Visualization of Neutrophil Extracellular Traps in Mesenteric Venules After Mesenteric Ischemia-Reperfusion Injury via Intravital Microscopy
Published on: September 27, 2024
Immunopathogenesis of ischemia/reperfusion-associated tissue damage
Antonis Ioannou1, Jurandir Dalle Lucca, George C Tsokos
1Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA. aioannou@bidmc.harvard.edu
Ischemia/reperfusion injury involves complex immune responses causing tissue damage. Targeting innate and adaptive immunity shows promise in limiting this damage in preclinical models.
Area of Science:
- Immunology
- Pathophysiology
- Transplantation
Background:
- Ischemia/reperfusion (IR) injury is a significant clinical problem in trauma, transplantation, and revascularization.
- IR triggers complex inflammatory cascades leading to local tissue damage.
- Both innate and adaptive immune responses play critical roles in IR-induced tissue injury.
Purpose of the Study:
- To review preclinical experimental data on the immune response's role in IR-induced tissue damage.
- To identify potential therapeutic targets within the immune system for mitigating IR injury.
Main Methods:
- Systematic review of pre-clinical studies investigating immune mechanisms in IR injury.
- Analysis of interventions targeting various components of the innate and adaptive immune systems.
Main Results:
- Distinct elements of both innate and adaptive immunity contribute to IR-related tissue damage.
- Preclinical interventions targeting natural antibodies, complement, Toll-like receptors, lymphocytes, and inflammatory mediators effectively limit IR injury.
- Strategies include preventing antibody binding, inhibiting complement activation, modulating Toll-like receptors, depleting B or T cells, and blocking cytokines/chemokines.
Conclusions:
- The immune response is a key driver of tissue damage following ischemia/reperfusion.
- Targeting specific immune pathways offers promising therapeutic strategies for IR injury.
- Further clinical trials are necessary to validate these preclinical findings and determine therapeutic efficacy.
Related Concept Videos
Ischemic Stroke ll: Pathophysiology
Cellular Injury IV: Necrosis
Cellular Injury I: Introduction
Myocarditis I: Introduction
Secondary Spinal Cord Injury llI: Pathophysiology
Chronic Inflammation: Introduction

